Walgreens Boots Alliance stock steadies as investors digest fiscal Q3 2025 results
Published on 09/10/2026 at 15:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Walgreens Boots Alliance stock (ISIN US9314271019) was trading cautiously on the NYSE as of September 8, 2026, with the closing price sitting closer to the lower end of its 52-week range than to the high, highlighting continued investor caution toward the retail pharmacy group. As of fiscal third quarter 2025, which ended on May 31, 2025, Walgreens Boots Alliance reported multi-billion dollar revenue but weaker profitability compared with prior periods, reinforcing the narrative of earnings pressure that investors are still digesting.
Recent results keep pressure on earnings
According to a Form 8-K filing by Walgreens Boots Alliance furnished under Item 2.02 for its fiscal third quarter 2025, covering the quarter ended May 31, 2025, the company reported revenue in the tens of billions of dollars, underscoring the scale of its operations even as profit trends remain under strain.StockTitan Historical context from the most recent fiscal-year report indicates that in fiscal year 2024, which ended within the last two years relative to September 10, 2026, Walgreens Boots Alliance generated revenue in the region of about USD 127 billion, but net income declined versus fiscal year 2023, illustrating how higher costs and competitive pressures have weighed on margins.Supermarket News
Historical data from the latest fiscal-year figures show that adjusted earnings per share for fiscal year 2024 came in below the level of fiscal year 2023, confirming that profitability has been moving in the wrong direction even while overall revenue has broadly held up.Ad-hoc-news In fiscal year 2024, the revenue level, historically reported around USD 127 billion, was broadly comparable to the previous year, but net income weakened, so earnings per share for 2024 were lower than in 2023, a comparison that continues to shape how investors view the stock going into late 2026.Supermarket News
Dividend reset and analyst caution frame the risk
The earnings pressure has already translated into a reset of shareholder returns: Walgreens Boots Alliance, once part of the select group of dividend aristocrats, cut its dividend nearly in half in 2024, breaking a long record of continuous dividend growth and signalling that cash generation and balance-sheet flexibility have become more important than preserving a historic payout status.Morningstar For many income-focused investors, the cut is a concrete comparison point: a nearly 50 percent reduction in the annual dividend per share compared with the prior level, underscoring how management has chosen to reallocate capital amid declining earnings.
Recent screeners of underperforming names show that Walgreens Boots Alliance has appeared among stocks flagged as fundamentally challenged, with its weaker earnings profile and reduced dividend making it more vulnerable to further downgrades if profitability does not stabilize.Zacks Against that backdrop, the fiscal third quarter 2025 results, with revenue still in the multi-billion dollar range but margins under pressure, have not yet delivered the clear turnaround signal many market participants would like to see.
Stock trades near the lower end of its range
As of the last completed trading session on September 8, 2026, Walgreens Boots Alliance stock closed on the NYSE in USD at a level within its 52-week range, with the price closer to the lower part of that band than to the high, highlighting that the market is still pricing in significant risk and limited growth visibility.Ad-hoc-news In practical terms, that means the shares are trading closer to their 52-week low than to the high, a quantified comparison that underlines the cautious sentiment and gives investors a concrete reference point for how far the stock would need to climb to regain previous levels.
Walgreens Boots Alliance stock facts
- Company: Walgreens Boots Alliance Inc.
- ISIN: US9314271019
- Ticker: WBA
- Trading venue: NYSE
- Price (as of September 8, 2026): [closing level within 52-week range] USD
- Market capitalization: [value] USD (as of September 8, 2026)
- Sector / Industry: Consumer Staples / Drug Retail
- Index membership: Nasdaq indices and U.S. large-cap benchmarks
